Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Palese

Showing results (191-200 of 291) with videos related to

Pageof 30
Sort By:
Cell|July 4, 2015
Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine EfficacyTaia T Wang, Jad Maamary, Gene S Tan, et al.
Nature Communications|October 27, 2010
Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virusRafael A Medina, Balaji Manicassamy, Silke Stertz, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 20, 2010
Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypesTaia T Wang, Gene S Tan, Rong Hai, et al.
Journal of Virology|February 15, 2013
H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and miceIrina Margine, Rong Hai, Randy A Albrecht, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 22, 2008
Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virusClaudia Pappas, Patricia V Aguilar, Christopher F Basler, et al.
Journal of Virology|February 26, 2010
PB1-F2 expression by the 2009 pandemic H1N1 influenza virus has minimal impact on virulence in animal modelsRong Hai, Mirco Schmolke, Zsuzsanna T Varga, et al.
Journal of Virology|September 12, 2014
Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutininGene S Tan, Peter S Lee, Ryan M B Hoffman, et al.
Vaccines|January 14, 2021
Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret ModelWen-Chun Liu, Raffael Nachbagauer, Daniel Stadlbauer, et al.
Molecular Therapy. Methods & Clinical Development|September 6, 2021
Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in miceAlec W Freyn, Matthew Pine, Victoria C Rosado, et al.
Mbio|March 24, 2016
Cryo-electron Microscopy Structures of Chimeric Hemagglutinin Displayed on a Universal Influenza Vaccine CandidateErin E H Tran, Kira A Podolsky, Alberto Bartesaghi, et al.
Pageof 30

Showing results (191-200 of 291) with videos related to

Sort By:
Pageof 30
Cell|July 4, 2015
Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine EfficacyTaia T Wang, Jad Maamary, Gene S Tan, et al.
Nature Communications|October 27, 2010
Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virusRafael A Medina, Balaji Manicassamy, Silke Stertz, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 20, 2010
Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypesTaia T Wang, Gene S Tan, Rong Hai, et al.
Journal of Virology|February 15, 2013
H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and miceIrina Margine, Rong Hai, Randy A Albrecht, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 22, 2008
Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virusClaudia Pappas, Patricia V Aguilar, Christopher F Basler, et al.
Journal of Virology|February 26, 2010
PB1-F2 expression by the 2009 pandemic H1N1 influenza virus has minimal impact on virulence in animal modelsRong Hai, Mirco Schmolke, Zsuzsanna T Varga, et al.
Journal of Virology|September 12, 2014
Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutininGene S Tan, Peter S Lee, Ryan M B Hoffman, et al.
Vaccines|January 14, 2021
Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret ModelWen-Chun Liu, Raffael Nachbagauer, Daniel Stadlbauer, et al.
Molecular Therapy. Methods & Clinical Development|September 6, 2021
Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in miceAlec W Freyn, Matthew Pine, Victoria C Rosado, et al.
Mbio|March 24, 2016
Cryo-electron Microscopy Structures of Chimeric Hemagglutinin Displayed on a Universal Influenza Vaccine CandidateErin E H Tran, Kira A Podolsky, Alberto Bartesaghi, et al.
Pageof 30